383 related articles for article (PubMed ID: 33237900)
1. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.
Holm M; Andersson E; Osterlund E; Ovissi A; Soveri LM; Anttonen AK; Kytölä S; Aittomäki K; Osterlund P; Ristimäki A
PLoS One; 2020; 15(11):e0239819. PubMed ID: 33237900
[TBL] [Abstract][Full Text] [Related]
2. Performance of four platforms for KRAS mutation detection in plasma cell-free DNA: ddPCR, Idylla, COBAS z480 and BEAMing.
Vessies DCL; Greuter MJE; van Rooijen KL; Linders TC; Lanfermeijer M; Ramkisoensing KL; Meijer GA; Koopman M; Coupé VMH; Vink GR; Fijneman RJA; van den Broek D
Sci Rep; 2020 May; 10(1):8122. PubMed ID: 32415199
[TBL] [Abstract][Full Text] [Related]
3. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.
Vivancos A; Aranda E; Benavides M; Élez E; Gómez-España MA; Toledano M; Alvarez M; Parrado MRC; García-Barberán V; Diaz-Rubio E
Sci Rep; 2019 Jun; 9(1):8976. PubMed ID: 31222012
[TBL] [Abstract][Full Text] [Related]
5. KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.
Pinheiro M; Peixoto A; Rocha P; Veiga I; Pinto C; Santos C; Pinto P; Guerra J; Escudeiro C; Barbosa A; Silva J; Teixeira MR
Int J Colorectal Dis; 2022 Apr; 37(4):895-905. PubMed ID: 35303157
[TBL] [Abstract][Full Text] [Related]
6. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A
Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.
Franczak C; Witz A; Geoffroy K; Demange J; Rouyer M; Husson M; Massard V; Gavoille C; Lambert A; Gilson P; Gambier N; Scala-Bertola J; Merlin JL; Harlé A
PLoS One; 2020; 15(1):e0227294. PubMed ID: 31940389
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy.
Wahl SGF; Dai HY; Emdal EF; Ottestad AL; Dale VG; Richardsen E; Halvorsen TO; Grønberg BH
J Pathol Clin Res; 2021 May; 7(3):209-219. PubMed ID: 33502820
[TBL] [Abstract][Full Text] [Related]
9. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
11. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
12. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
[TBL] [Abstract][Full Text] [Related]
13. Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial.
Lueong SS; Herbst A; Liffers ST; Bielefeld N; Horn PA; Tannapfel A; Reinacher-Schick A; Hinke A; Hegewisch-Becker S; Kolligs FT; Siveke JT
Clin Chem; 2020 Dec; 66(12):1510-1520. PubMed ID: 33257977
[TBL] [Abstract][Full Text] [Related]
14. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing.
Macgregor-Das A; Yu J; Tamura K; Abe T; Suenaga M; Shindo K; Borges M; Koi C; Kohi S; Sadakari Y; Dal Molin M; Almario JA; Ford M; Chuidian M; Burkhart R; He J; Hruban RH; Eshleman JR; Klein AP; Wolfgang CL; Canto MI; Goggins M
J Mol Diagn; 2020 Jun; 22(6):748-756. PubMed ID: 32205290
[TBL] [Abstract][Full Text] [Related]
15. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
16. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.
Sclafani F; Chau I; Cunningham D; Hahne JC; Vlachogiannis G; Eltahir Z; Lampis A; Braconi C; Kalaitzaki E; De Castro DG; Wotherspoon A; Capdevila J; Glimelius B; Tarazona N; Begum R; Lote H; Hulkki Wilson S; Mentrasti G; Brown G; Tait D; Oates J; Valeri N
Sci Rep; 2018 Jan; 8(1):1445. PubMed ID: 29362371
[TBL] [Abstract][Full Text] [Related]
17. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients.
Crisafulli G; Mussolin B; Cassingena A; Montone M; Bartolini A; Barault L; Martinetti A; Morano F; Pietrantonio F; Sartore-Bianchi A; Siena S; Di Nicolantonio F; Marsoni S; Bardelli A; Siravegna G
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32149725
[TBL] [Abstract][Full Text] [Related]
18. Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer.
Jia N; Chang L; Gao X; Shi X; Dou X; Guan M; Shao Y; Li N; Cheng Y; Ying H; Sun Z; Zhou Y; Zhao L; Zhou J; Bai C
BMC Cancer; 2021 Jul; 21(1):845. PubMed ID: 34294055
[TBL] [Abstract][Full Text] [Related]
19. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA.
Hussung S; Follo M; Klar RFU; Michalczyk S; Fritsch K; Nollmann F; Hipp J; Duyster J; Scherer F; von Bubnoff N; Boerries M; Wittel U; Fritsch RM
J Mol Diagn; 2020 Jul; 22(7):943-956. PubMed ID: 32376474
[TBL] [Abstract][Full Text] [Related]
20. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
